We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Crelux Receives EU Funding to Develop Next Generation Protein Expression Tools

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Crelux Receives EU Funding to Develop Next Generation Protein Expression Tools"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

The availability of high quality proteins and protein complexes is essential to most areas of modern drug discovery. Protein applications range from use in assays and diagnostics all the way to structure based drug discovery.

Being a world leading supplier of premium quality proteins and protein crystallography services, Crelux has heavily invested early on in developing and advancing leading edge protein expression systems and is constantly optimizing tools and processes for eukaryotic expression systems.

In recognition of the leading edge position of Crelux in the advancement of high quality protein production, 5.9 Mio € have been granted by the EU to the newly launched research project ComplexINC that is co-coordinated by Crelux.

Over the next four years this consortium of world experts from industry and academia will apply synthetic biology approaches to move eukaryotic protein expression systems to a new level.

Next generation tool-kits and engineered cell lines will be developed for yeast, insect cell and mammalian cell expression of proteins and protein complexes that will dramatically reduce the time to product for research proteins and enable the production of proteins and large protein complexes that are difficult or impossible to produce with today's technologies.

"Crelux is dedicated to provide its global customers with only the highest quality of proteins and protein services. With existing technologies however, a large number of validated drug targets cannot be produced at all or only in a poor functional state with limited activity and solubility. This is particularly true for the rapidly growing group of large protein complexes that are identified as highly relevant drug targets for example in fields like epigenetics. I am therefore delighted that the generous EU funding allows Crelux to significantly advance the state of the art for the production of complex biologics in close collaboration within a tight network of international experts." commented Ismail Moarefi, executive director of science and technology at Crelux.